Because the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib and
the multitargeted antifolate pemetrexed are registered in the treatment of second-line non …

Purpose: This study was undertaken to select the optimal combination schedule of erlotinib
and pemetrexed for the treatment of relapsed non–small cell lung cancer (NSCLC) using a …

Currently, chemotherapy and targeted therapies share the principal limitation of the
emergence of drug resistance, which prevents these strategies from having lasting clinical …

Combination of drugs with different targets is a logical approach to overcome multilevel
cross-stimulation among key pathways in NSCLC progression such as EGFR, K-Ras and …

Activating epidermal growth factor receptor (EGFR) mutations have been linked with
sensitivity to gefitinib and erlotinib; however, there are no established predictive markers for …

Erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor,
has clinical activity in advanced lung cancer, but disease that initially responds to erlotinib …

Purpose: Epidermal growth factor receptor (EGFR) kinase inhibitors induce dramatic clinical
responses in a subset of non-small cell lung cancer (NSCLC) patients with advanced …

Introduction: Most epidermal growth factor receptor (EGFR) mutant non-small cell lung
cancers (NSCLCs) are sensitive to EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib …

Introduction: Patients with epidermal growth factor receptor (EGFR) mutation positive non–
small-cell lung cancer exhibited marked response to gefitinib or erlotinib. In most cases …

Background and Purpose Intrinsic and/or acquired resistance of epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors (TKIs) commonly occurs in patients with non …